PT1028738E - Utilizacao de citoquinas e mitogenios para inibir respostas imunitarias patologicas - Google Patents

Utilizacao de citoquinas e mitogenios para inibir respostas imunitarias patologicas

Info

Publication number
PT1028738E
PT1028738E PT98957605T PT98957605T PT1028738E PT 1028738 E PT1028738 E PT 1028738E PT 98957605 T PT98957605 T PT 98957605T PT 98957605 T PT98957605 T PT 98957605T PT 1028738 E PT1028738 E PT 1028738E
Authority
PT
Portugal
Prior art keywords
mitogens
cytokines
inhibit pathological
immunity responses
pathological immunity
Prior art date
Application number
PT98957605T
Other languages
English (en)
Portuguese (pt)
Inventor
David A Horwitz
Original Assignee
Univ Southern California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Southern California filed Critical Univ Southern California
Publication of PT1028738E publication Critical patent/PT1028738E/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/22—Immunosuppressive or immunotolerising
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/416—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/15—Transforming growth factor beta (TGF-β)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C12N2501/599—Cell markers; Cell surface determinants with CD designations not provided for elsewhere

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PT98957605T 1997-11-05 1998-11-05 Utilizacao de citoquinas e mitogenios para inibir respostas imunitarias patologicas PT1028738E (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US6450797P 1997-11-05 1997-11-05

Publications (1)

Publication Number Publication Date
PT1028738E true PT1028738E (pt) 2003-08-29

Family

ID=22056456

Family Applications (1)

Application Number Title Priority Date Filing Date
PT98957605T PT1028738E (pt) 1997-11-05 1998-11-05 Utilizacao de citoquinas e mitogenios para inibir respostas imunitarias patologicas

Country Status (11)

Country Link
US (1) US6228359B1 (enExample)
EP (1) EP1028738B1 (enExample)
JP (1) JP4309047B2 (enExample)
AT (1) ATE238061T1 (enExample)
AU (1) AU747767B2 (enExample)
CA (1) CA2309115C (enExample)
DE (1) DE69813868T2 (enExample)
DK (1) DK1028738T3 (enExample)
ES (1) ES2198774T3 (enExample)
PT (1) PT1028738E (enExample)
WO (1) WO1999025366A1 (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6358506B1 (en) * 1997-11-05 2002-03-19 University Of Southern California Use of cytokines and mitogens to inhibit pathological immune responses
US20030157057A1 (en) * 1999-05-05 2003-08-21 Horwitz David A. Methods for the induction of professional and cytokine-producing regulatory T cells
EP1061949B1 (en) 1998-03-03 2009-07-15 University of Southern California Cytokines and mitogens to inhibit graft-versus-host disease
US6803036B1 (en) 1998-03-03 2004-10-12 University Of Southern California Use of cytokines, cells and mitogens to inhibit graft versus host disease
ES2311462T3 (es) * 1999-05-05 2009-02-16 University Of Southern California Uso de citocinas y mitogenos para inhibir las respuestas inmunes patologicas.
ATE431399T1 (de) * 1999-09-01 2009-05-15 Univ Southern California Verwendung von cytokinen, zellen und mitogene zur hemmung der graft-versus-host krankheit
AU2007202534B2 (en) * 2000-04-11 2011-06-09 University Of Southern California A method to prevent graft rejection using TGF-beta to induce T suppressor cells
ATE460475T1 (de) 2000-04-11 2010-03-15 Univ Southern California Methode zur verhinderung der transplantatabstossung unter verwendung von tgf- beta zur induktion von t-suppressorzellen
AU2002364230B2 (en) * 2001-12-21 2008-05-01 University Of Southern California Methods for the induction of professional and cytokine-producing regulatory cells
US20050202010A1 (en) * 2003-08-29 2005-09-15 Giroir Brett P. Method of treatment and bioassay involving macrophage migration inhibitory factor (MIF) as cardiac-derived myocardial depressant factor
CN102971416B (zh) 2010-04-22 2018-03-30 南加州大学 用于扩增和稳定天然调节性t细胞的方法和组合物
EP2763692A2 (en) 2011-10-06 2014-08-13 European Molecular Biology Laboratory Use of igf-1 in the modulation of treg cell activity and the treatment and prevention of autoimmune disorders or diseases
AU2012320597C1 (en) 2011-10-07 2015-10-15 Baxalta GmbH oxMIF as a diagnostic marker
WO2013173076A1 (en) 2012-05-04 2013-11-21 University Of Southern California Methods and compositions for generating and using allogeneic suppressor cells
GB201421716D0 (en) * 2014-12-05 2015-01-21 King S College London Cell expansion procedure

Also Published As

Publication number Publication date
WO1999025366A1 (en) 1999-05-27
DE69813868T2 (de) 2004-03-04
CA2309115C (en) 2010-10-19
DE69813868D1 (de) 2003-05-28
ES2198774T3 (es) 2004-02-01
DK1028738T3 (da) 2003-08-11
AU747767B2 (en) 2002-05-23
ATE238061T1 (de) 2003-05-15
AU1382799A (en) 1999-06-07
JP4309047B2 (ja) 2009-08-05
US6228359B1 (en) 2001-05-08
EP1028738A1 (en) 2000-08-23
EP1028738B1 (en) 2003-04-23
CA2309115A1 (en) 1999-05-27
JP2001523443A (ja) 2001-11-27

Similar Documents

Publication Publication Date Title
ATE238061T1 (de) Verwendung von zytokinen und mitogenen für inhibierung von pathologischen immunantworten
AR243600A1 (es) Un aparato para el tratamiento de muestras biologicas y microbiologicas.
GB9818916D0 (en) Use
DE69633679D1 (de) Substituierte aryl-oder heteroarylamide mit retinoid-ähnlicher biologischer aktivität
DE69725153D1 (de) Kaliumkanal-blocker
DE3676929D1 (de) Schwefelenthaltende zusammensetzung und konzentrate und schmieroele die diese enthalten.
ES2099158T3 (es) Tratamiento del rechazo de trasplantes o de enfermedades autoinmunitarias y complejo de la formula general x-pro-y-boropro asociada al mismo.
AU4416096A (en) Acetylenes disubstituted with hydroxyaryl and aryl or heteroaryl groups having retinoid-like biological activity
EA199800667A1 (ru) Новые фенантридины
NO902188L (no) Kateter med tilbakestroemnings-innsnevring.
DE69423346D1 (de) Schnelles verfahren fur die dns sequenzierung und diagnostische anwendungen
PT804196E (pt) Utilizacao de antagonistas de serotonina (5ht3) para o tratamento de fibromialgia
NZ294446A (en) Stem cell proliferation inhibitors, haemoglobin chains used for the treatment of autoimmune diseases.
DE69313097D1 (de) Chirurgische und/oder klinische vorrichtung.
DE3773649D1 (de) Behandlungsverfahren und system fuer bohrschlaemme und dergl.
MX9303127A (es) Metodo para reducir selectivamente la poblacion celular de leucocitos.
MX164854B (es) Procedimiento para el tratamiento de copolimero de etileno/monoxido de carbono
ES2013631B3 (es) Metodo para el tratamiento de tejidos.
IT8224081A0 (it) Procedimento, dispositivo e disposizione di regolazione per trattare rottame di metallo duro mediante alligatura.
FR2491334B1 (enExample)
DE3687097D1 (de) Therapeutisches mittel zur behandlung haematopoietischer krankheiten.
WO1996002240A3 (en) Use of inhibitors of human s-cd23
WO2000066158A3 (en) Use of cytokines and mitogens to inhibit pathological immune responses
DE69007374D1 (de) Injektionssystem für die Behandlung von Zellen.
PT1092040E (pt) Metodos de inibicao helicobacter pylori